Restylane® for the Treatment of Tear Trough Deformity

Inclusion Criteria: 1. Female; 2. Age of 18 years or greater; 3. Indication for treatment of bilateral tear trough deformity; 4. Symmetry of tear trough deformity at baseline; 5. Subjects who understood and signed the Informed Consent Form (ICF) when entering the study, before performing any investigational procedure. Exclusion Criteria: 1. Prior (\<1 year) or planning to undergo any surgery in the corporal area of interest for study; 2. Any type of comorbidity or clinical condition that, at investigator's discretion, could interfere with study assessments; 3. Diabetes mellitus type 1 or type 2; 4. Autoimmune diseases, collagenosis, decompensated endocrine diseases or any disease that, at investigator's discretion, could interfere with study assessments; 5. Using or have used within 3 months drugs such as corticosteroids, immunosuppressants or others collagen-production inhibitors; 6. Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months; 7. Pregnant or breastfeeding, or wishes to get pregnant within the next 12 months, or refuses to use appropriate contraceptive method (in case of women of childbearing potential); 8. Restylane® should not be used in any person who has hypersensitivity to any of the components of the product; 9. Active skin inflammation or infection in or near the treatment area; 10. Possessing any of the contraindications for use of Restylane®; 11. Septal fat herniation; 12. Severe elastosis (e.g., dermatochalasis); 13. Use of Vitamin E, gingko biloba, Aspirin or non-steroidal anti-inflammatory drugs (NSAIDS) within 1 week of treatment. 14. Use of tear trough injections in the last 12 months. 15. Use of anterior midface injections in the last 12 months.